Technology | June 06, 2011

AngioDynamics Launches VenaCure 1470nm Laser for Treatment of Varicose Veins


June 6, 2011 – AngioDynamics has expanded its VenaCure EVLT System product offering with the global launch of the new VenaCure 1470nm laser to treat varicose veins with greater energy efficiency.

“Our VenaCure 1470 endovenous laser has shown to be highly efficient in the treatment of varicose veins, as it utilizes a lower power output compared with other lasers to achieve effective vein closure,” said Tom Kupec, Vice President of Marketing for AngioDynamics. “The new laser is complemented by the benefits of our NeverTouch gold-tip fiber, designed to result in improved procedure parameters for patients and physicians.”

The VenaCure 1470nm laser’s light energy is precisely delivered through the NeverTouch gold-tip fiber, and is more readily absorbed by the water in the blood and endothelial lining than is the case with other wavelengths. The NeverTouch fiber’s jacketed tip has been engineered to maximize clinical efficacy and minimize post-operative pain and bruising. It has a lower power density and is designed to virtually eliminate the risk of direct contact between the laser fiber and vein wall.

“Our research group found excellent vein closure rates, minimal postoperative discomfort and bruising, and a clear reduction in symptom severity over the follow-up period. By allowing for the more efficient transfer of energy to the vein, this new long wavelength laser translated into improved clinical outcomes as compared to short wavelength lasers we have studied,” said Jose I. Almeida, M.D., FACS, managing partner, Vascular Device Partners, LLC.

The VenaCure 1470nm lasers are manufactured in AngioDynamics’ Cambridge, U.K., facility, which has been established as a center of excellence and reliability. It has received the CE mark, and a 510 (k) approval.

For more information: www.VenaCure-EVLT.com, www.angiodynamics.com


Related Content

News | Venous Therapies

October 14, 2022 — Medtronic, a global leader in medical technology, announced the 36-month final results from the ABRE ...

Home October 14, 2022
Home
News | Venous Therapies

November 22, 2021 — Fewer than 10 days of low-molecular-weight heparin (LMWH) after stenting for extensive iliofemoral ...

Home November 22, 2021
Home
News | Venous Therapies

February 22, 2021 — The U.S. Food and Drug Administration (FDA) recently cleared the Cook Medical Zilver Vena Venous ...

Home February 22, 2021
Home
News | Venous Therapies

October 26, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic Abre venous self-expanding ...

Home October 26, 2020
Home
News | Venous Therapies

October 31, 2019 – In a large series of iliac vein stent cases, a blinded comparison found intravascular ultrasound ...

Home October 31, 2019
Home
Technology | Venous Therapies

May 6, 2019 — The U.S Food and Drug Administration (FDA) has cleared the Boston Scientific Vici Venous Stent System for ...

Home May 06, 2019
Home
Technology | Venous Therapies

April 3, 2019 — The U.S. Food and Drug Administration (FDA) recently cleared Bard Peripheral Vascular's Venovo Venous ...

Home April 03, 2019
Home
News | Venous Therapies

August 8, 2018 — Boston Scientific Corp. announced it has signed an agreement to acquire Veniti Inc., which has ...

Home August 08, 2018
Home
Feature | Venous Therapies | Tif Siragusa, M.D.

The introduction of thermal ablation revolutionized the treatment of varicose veins, yet recurrence remains a stubborn ...

Home April 30, 2018
Home
News | Venous Therapies

January 26, 2018 – Medtronic plc announced the initiation of its investigational device exemption (IDE) study for the ...

Home January 26, 2018
Home
Subscribe Now